November 19, 2024 C-Path’s TRxA Announces $1 Million Award for Drug Development Project in Type 1 Diabetes TUCSON, Ariz., November 19, 2024 — Critical Path Institute® (C-Path) today announced that its Translational Therapeutics Accele
November 13, 2024 C-Path Announces Gender Equitable Medicines for Parkinson’s Disease (GEM‑PD) Initiative C-Path expands its worldwide leadership in accelerating drug development in neurology; seeks additional collaborators to broaden..
November 7, 2024 C-Path Announces Key Leadership Appointments in Neurodegenerative Disease Research Dr. Diane Stephenson Promoted to Vice President of Neurology; Dr. Nadine Tatton Welcomed as New Executive Director of CPAD.
October 16, 2024 Sanford Health Rare Disease Data Registry and C-Path’s RDCA-DAP Enter into a Master Data Contribution Agreement to Aggregate Rare Disease Data Critical Path Institute (C-Path) is pleased to announce the expansion of our partnership with the Coordination...
October 1, 2024 The AMR Accelerator Calls to Action: European Capacity for Antibiotic R&D Requires Long-term Funding Note: You are reading this information because Critical Path Institute is a partner of both ERA4TB and Unite4TB.
September 30, 2024 C-Path to Lead Comprehensive Task Force Focused on Accelerating Drug Development for Limb-Girdle Muscular Dystrophies C-Path announced the formation of a new task for under its RDCA-DAP, dedicated to...
September 19, 2024 C-Path’s PKD Outcomes Consortium Receives BAA Award for Project to Advance Drug Development Tools for Autosomal Dominant Tubulointerstitial Kidney Disease C-Path is thrilled to announce its PKDOC has been awarded...
September 12, 2024 C-Path’s Inaugural Global Impact Conference Charts the Future of Drug Development C-Path successfully concluded its inaugural Global Impact Conference (CGIC) on September 11, 2024.
September 9, 2024 FDA Issues ‘Letter of Support’ Encouraging Use of Synuclein-based Biomarker, αSyn-SAA, in Clinical Trials in Parkinson’s and Related Diseases FDA) encouraged scientists and drug developers to use the alpha-synuclein seed amplification assay (αSyn-SAA) biomarker...
September 5, 2024 Cystic Fibrosis Therapeutics Development Network Contributes New Data Sets to C-Path’s RDCA-DAP, Advancing CF Research and Treatment Strategies Critical Path Institute (C-Path) today announced the addition of significant new data sets...
